PAR paradigm biopharmaceuticals limited..

Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-4

  1. 49 Posts.
    lightbulb Created with Sketch. 9
    Although there is a delay mentioned, I am more than happy to receive results on a 12 month investigation rather than 6, would save a hell of a lot of time to finish a 6 month project to then do another one for 12 months. I can only imagine the consultation and decisions PAR are making to really try and nail this all. Plus the canine study will be helpful as mentioned to showcase further DMOAD action ( I did not know 20 weeks of canine life equates to 3 human years..) can't wait to see what our Canine friends show us, maybe all this talk about Vets seeing DMOAD affects for years might be true after all (with actual evidence from biomarker/imaging rather than a anecdotal).

    Just give me a green light already, then again I'm loving these cheap shares..

    Have a great week all
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
42.0¢
Change
-0.020(4.55%)
Mkt cap ! $166.9M
Open High Low Value Volume
44.5¢ 44.5¢ 41.5¢ $271.6K 637.8K

Buyers (Bids)

No. Vol. Price($)
2 5960 42.0¢
 

Sellers (Offers)

Price($) Vol. No.
43.0¢ 3696 1
View Market Depth
Last trade - 16.10pm 16/07/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.